Skip to content

Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study

The Risk of Rupture or Growth in Patients With Small Unruptured Paraclinoid Aneurysm: Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02553109
Acronym
PANDORA
Enrollment
682
Registered
2015-09-17
Start date
2015-01-31
Completion date
2023-12-31
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unruptured Aneurysm of Carotid Artery

Keywords

small paraclinoid

Brief summary

The optimal consensus concerning treatment of incidental small paraclinoid unruptured intracranial aneurysms (UIAs) remains controversial. The aim of this prospective study is to reveal the natural history of small paraclinoid UIAs with the goal of informing the treatment plan.

Detailed description

A prospective observational study will be conducted in 13 Korean centers enrolling a consecutive series of 645 patients with small paraclinoid unruptured intracranial aneurysms (UIAs) from 2015 to 2017. The investigators defined the cohort population as adults(20 years old or more) with small (less than 5mm) unruptured paraclinoid aneurysm. To determine the growth rate and risk factors, the angiographic features based on MRA or CTA(ex) size, arterial relationship, multiplicity)and the clinical characteristics (ex) age, hypertension (HTN), diabetes mellitus(DM), Hyperlipidemia, smoking) are recorded at initial visit, 1 year, 2years, 3years, and 5years. The cumulative risk and the risk factors of aneurysmal rupture and growth will be analysed.

Interventions

None listed

Sponsors

Seoul National University Bundang Hospital
CollaboratorOTHER
SMG-SNU Boramae Medical Center
CollaboratorOTHER
DongGuk University
CollaboratorOTHER
Inje University
CollaboratorOTHER
Jeju National University Hospital
CollaboratorOTHER
KangWon National University Hospital
CollaboratorOTHER
Gyeongsang National University Hospital
CollaboratorOTHER
Soonchunhyang University Hospital
CollaboratorOTHER
Samsung Medical Center
CollaboratorOTHER
Asan Medical Center
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with newly diagnosed small unruptured paraclinoid aneurysms who agreed to participate. * 20years old or more * less than 5mm in maximum diameter * neurological status of patients should be satisfied with less than modified Rankin score 2 or more than 70 in Karnofsky performance score

Exclusion criteria

* patients had previous subarachnoid hemorrhage that could be related to the rupture of paraclinoid aneurysm. * traumatic, infectious or dissecting aneurysms * fusiform aneurysms * aneurysms that related to other vascular disease or brain tumor * aneurysm that associated with the atherosclerotic change of a parent artery

Design outcomes

Primary

MeasureTime frameDescription
Number of increased maximal diameter of enrolled paraclinoid aneurysms on follow up MRA or CTAwithin 5years after enrollmentIf, the maximal diameter(in mm) of aneurysm which is measured by 1 neurosurgeon and 1 neuroradiologist on follow up MRA or CTA (1,2,3,5 year follow up) is 1.5 times bigger than on initial MRA or CTA, investigators will decide that the aneurysm is increased.
Number of rupture of enrolled paraclinoid aneurysmswithin 5years after enrollmentannual rupture rate

Secondary

MeasureTime frameDescription
Mortality rate of enrolled patients(related to rupture of aneurysm or not)within 5years after enrollmentdeath due to ruptured aneurysm
Number of participants with worsened modified Rankin scale scorewithin 5years after enrollmentfrom 0(No symptom at all) to 6(Dead)
Number of participants with worsened Karnofsky Performance Status scalewithin 5years after enrollmentfrom 0(Dead) to 100(Normal)
Treatment(due to growth or rupture) rate of enrolled aneurysmswithin 5years after enrollment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026